V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10449561 | 10057570 | 1.81 | 81.5 | null | null | 2020-02-04 | GEMCITABINE + PACLITAXEL ALBUMIN (ABRAXANE) | 02 | null | GEMCITABINE + NAB-PACLITAXEL | 100469931 |
| 10449977 | 10057572 | 1.66 | 78.2 | null | 2018-02-08 | 2018-02-09 | Liposomal Doxorubicin 50mg/m2 | 02 | null | PEMETREXED | 101325616 |
| 10450089 | 10057574 | 1.72 | 93.4 | null | 2021-02-06 | 2021-02-06 | Rucaparib | 02 | null | DURVALUMAB | 101036602 |
| 10450327 | 10057575 | 1.69 | 64.8 | Curative (C) | null | 2021-03-13 | Cyclophos + Dex + Lenalidomide | 02 | N | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 100638667 |
| 10450454 | 10057576 | null | 89.9 | Palliative (P) | 2018-05-07 | 2018-05-10 | Thalidomide 50mg | 02 | N | METHOTREXATE INTRATHECAL | 101208450 |
| 10451435 | 10057580 | 1.67 | 76.6 | null | 2019-08-12 | 2019-08-13 | Everolimus 10mg | 02 | null | GEMCARBO | 100533230 |
| 10451466 | 10057581 | null | null | 03 | 2019-07-14 | 2019-07-20 | CHLORAMBUCIL + RITUXIMAB | 02 | N | ISATUXIMAB + POMALIDOMIDE | 101657859 |
| 10451495 | 10057582 | 1.7 | 55.5 | Disease modification (D) | 2019-02-23 | 2019-05-01 | null | 02 | N | INTERFERON ALFA | 100123789 |
| 10451525 | 10057583 | 1.71 | 54.6 | Palliative (P) | 2021-11-02 | 2021-11-02 | Everolimus 10mg | 02 | N | BOSUTINIB | 101813115 |
| 10451540 | 10057584 | 1.68 | 82.4 | Adjuvant (A) | 2017-02-14 | 2017-02-14 | null | 02 | N | CAPECITABINE + CISPLATIN | 101579165 |
| 10451574 | 10057585 | 1.67 | 90 | Curative (C) | null | 2019-06-07 | null | 02 | N | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + RITUXIMAB | 101833820 |
| 10451624 | 10057586 | 1.85 | 66.7 | null | 2011-09-06 | 2020-01-17 | INTERFERON | 02 | null | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100630641 |
| 10451796 | 10057588 | 0 | 0 | Palliative (P) | 2019-11-16 | 2019-11-23 | CAPECITABINE + CARBOPLATIN | N | N | PEMETREXED | 100355081 |
| 10451938 | 10057589 | 1.73 | 77.6 | null | 2019-08-30 | 2019-09-21 | FLUOROURACIL + OXALIPLATIN + Trastuzumab | 02 | null | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 100580358 |
| 10452468 | 10057592 | 1.52 | 0 | Palliative (P) | 2019-11-08 | 2019-11-10 | Eribulin | 02 | N | CYCLOPHOSPHAMIDE + LENALIDOMIDE | 100730289 |
| 10452501 | 10057593 | null | null | Curative (C) | 2018-02-17 | 2018-03-14 | FLAIR trial | 02 | N | AZACITIDINE + VENETOCLAX | 100847502 |
| 10452517 | 10057594 | 1.79 | 96 | null | 2020-03-02 | 2020-03-14 | Carboplatin+Fluorouracil 4 or 5 day | 02 | null | GEMCITABINE + NAB-PACLITAXEL | 101749327 |
| 10453585 | 10057598 | 1.72 | 70.9 | null | 2018-09-04 | 2018-09-06 | PARTNER Trial | 02 | null | LENALIDOMIDE + RITUXIMAB | 101386551 |
| 10453660 | 10057599 | 0 | 66 | null | 2021-10-19 | 2021-10-19 | PCV | N | null | IRINOTECAN + MDG | 101746091 |
| 10454229 | 10057600 | 0 | 73.4 | Adjuvant (A) | 2016-10-26 | 2017-06-06 | Tivozanib | 02 | N | NILOTINIB | 101420082 |
| 10454508 | 10057602 | 1.75 | 70 | null | 2019-10-03 | 2019-10-03 | R GCVP | 02 | null | TRIAL | 100364572 |
| 10454560 | 10057603 | 1.79 | 40.8 | Palliative (P) | null | 2019-02-25 | Durvalumab | 02 | N | METHOTREXATE INTRATHECAL | 100104553 |
| 10454575 | 10057604 | 1.68 | null | null | 2017-09-28 | 2017-09-29 | Chlorambucil + Pred + Rituximab | 02 | null | AML18 TRIAL | 101407185 |
| 10454721 | 10057605 | 1.63 | 66.8 | Disease modification (D) | 2021-08-06 | 2021-08-20 | LENVATINIB | 02 | null | LENALIDOMIDE + RITUXIMAB | 101295477 |
| 10454792 | 10057606 | 1.84 | 83.35 | Palliative (P) | 2018-07-29 | 2018-08-01 | ABEMACICLIB + FULVESTRANT | 2 | N | BENDAMUSTINE + OBINUTUZUMAB | 101314395 |
| 10454916 | 10057608 | 1.86 | null | null | 2019-07-26 | 2019-07-28 | TRASTUZUMAB EMTANSINE | null | null | BCG | 101332640 |
| 10455029 | 10057609 | null | null | null | 2021-08-30 | 2022-04-21 | MUK 8 TRIAL | 02 | null | FULVESTRANT + PALBOCICLIB | 101250468 |
| 10455223 | 10057611 | null | null | Curative (C) | 2019-09-28 | 2019-09-29 | null | 02 | N | IXAZOMIB | 100792259 |
| 10455322 | 10057612 | 1.6 | 44.9 | null | 2017-12-18 | 2018-02-26 | MPT | 02 | null | CAPECITABINE + CISPLATIN | 100027122 |
| 10455346 | 10057613 | 1.82 | 46 | 03 | 2018-12-27 | 2018-12-27 | Sunitinib | 02 | N | CAPECITABINE + CISPLATIN | 101620200 |
| 10455474 | 10057614 | 1.78 | 72.3 | Neo-adjuvant (N) | 2020-03-24 | 2020-04-07 | Dacarbazine | 2 | N | CAPECITABINE + GEMCITABINE | 101712799 |
| 10455491 | 10057615 | 1.62 | 106 | null | 2018-10-09 | 2018-10-24 | Midostaurin | 02 | null | CARDAMON TRIAL | 100792335 |
| 10455582 | 10057616 | 1.67 | 83 | null | 2021-08-26 | 2021-09-01 | Pazopanib | 02 | null | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 101346254 |
| 10455599 | 10057617 | 1.7 | 72.8 | Palliative (P) | 2018-06-01 | 2018-06-01 | RIALTO TRIAL | 02 | N | NERATINIB | 101486861 |
| 10456094 | 10057620 | 0 | 0 | null | 2021-10-12 | 2022-01-22 | null | 01 | null | DOCETAXEL + NINTEDANIB | 100470356 |
| 10456152 | 10057621 | 1.52 | 61.6 | Palliative (P) | 2019-02-15 | 2019-02-15 | null | 02 | N | CAPECITABINE + CISPLATIN | 101823908 |
| 10456186 | 10057622 | 1.67 | 68.2 | 03 | 2019-05-25 | 2019-06-05 | ANAGRELIDE | 02 | N | LOMUSTINE | 100520601 |
| 10456315 | 10057623 | null | null | 03 | 2020-11-15 | 2020-11-15 | IDARUBICIN + MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | 02 | N | UKALL60+ | 100751880 |
| 10456500 | 10057624 | 1.74 | 104 | null | 2019-06-14 | 2019-06-27 | Capecitabine + Cisplatin | 02 | null | OSIMERTINIB | 101412367 |
| 10456645 | 10057625 | 1.8 | 97.5 | null | 2020-06-07 | 2021-03-13 | null | 02 | null | CERITINIB | 100479830 |
| 10456714 | 10057627 | 1.86 | 77.2 | null | 2019-07-07 | 2020-01-01 | Sunitinib | N | null | FLUOROURACIL + MITOMYCIN | 100010540 |
| 10456759 | 10057628 | 1.7 | 71.2 | Palliative (P) | 2019-12-28 | 2020-01-04 | LIPOSOMAL DAUNORUBICIN + CYTARABINE (Vyxeos) | N | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101132474 |
| 10456807 | 10057630 | 1.83 | 84.7 | Palliative (P) | 2019-06-15 | 2019-06-29 | Doxorubicin + Olaratumab | null | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + RITUXIMAB + VINCRISTINE | 101200136 |
| 10456923 | 10057631 | 1.84 | 61.8 | Disease modification (D) | 2020-02-13 | 2020-05-05 | Cisplatin + Pemetrexed | 02 | N | ANAGRELIDE | 100001107 |
| 10457185 | 10057633 | 1.7 | 63.5 | null | 2018-04-04 | 2018-10-09 | EVEROLIMUS | 02 | null | BRENTUXIMAB | 101304930 |
| 10457276 | 10057634 | 1.62 | 68.6 | Palliative (P) | 2018-01-06 | 2018-01-07 | ABEMACICLIB + FULVESTRANT | 02 | N | CARBOPLATIN + DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 100101604 |
| 10457480 | 10057635 | 1.82 | 49.8 | null | 2018-08-10 | 2018-08-10 | Cisplatin + Docetaxel | N | null | FEDRATINIB | 100480975 |
| 10457652 | 10057637 | 1.67 | 78.6 | Palliative (P) | 2019-12-02 | 2019-12-09 | GEMCITABINE + NAB PACLITAXEL | 02 | N | STAR TRIAL | 100893378 |
| 10457743 | 10057638 | 1.82 | 69.9 | Palliative (P) | 2018-03-30 | 2018-04-02 | null | 02 | N | ELOQUENT2 TRIAL | 100085056 |
| 10457867 | 10057639 | null | null | null | 2018-12-23 | 2020-04-12 | EC | 02 | null | ISATUXIMAB + POMALIDOMIDE | 100435008 |